PARTICIPATION OF IASIS PHARMA IN THE “24th PANHELLENIC CONGRESS OF HYPERTENSION”

25/11/2024|All articles, Press Room, Product launches, Scientific conferences|

 07/11 – 09/11 2024 Grand Hyatt/Athens IASIS PHARMA participated in the “24th PANHELLENIC CONGRESS OF HYPERTENSION” which was held from 07/11 to 09/11 2024, at the Grand Hyatt Hotel/Athens. The conference was organized by the Hellenic Society of Hypertension (HSH). IASIS PHARMA presented at its exhibition stand the following products:  RosuZet®: New Product Launching. Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages [...]

Read More

NEW PRODUCT LAUNCHING: RosuZet®

22/05/2024|All articles, Company news, Product launches|

IASIS PHARMA is pleased to announce the RosuZet® launching, in the formulation of film-coated tablets. RosuZet® is the fixed dose combination of Rosuvastatin - Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents. RosuZet® [...]

Read More

NEW ZYLAPOUR® – ALLOPURINOL PACKAGING: 100 MG x 100 TABS

28/02/2024|All articles, Press Room, Product launches|

IASIS PHARMA is pleased to announce the launch of the new Zylapour® 100 mg x 100 tabs package, which expands the existing Zylapour® 100 mg x 30 tabs & Zylapour® 300 mg x 30 packages. The active substance of Zylapour® is Allopurinol. Allopurinol is in the class of medications called xanthine oxidase inhibitors and it was approved for medical [...]

Read More

NEW PRODUCT: CHIOS MASTIHA POWDER – mastiha var. Chia

28/11/2023|All articles, Exploiting the gifts of Greek nature, Press Room, Product launches|

Launching  the new Chios Mastiha in Powder (package of 15 sachets) expands the well-established Mastiha var.Chia brand. Dr. Christos Kon. Zavos, Gastroenterologist – Hepatologist introduced the product to PharmaQ sales force at the new facilities of Iasis Pharma in Koropi. Dr. Christos Kon. Zavos presented all the Updated Facts, Important Scientific Data & Newest Developments [...]

Read More

NEW PRODUCT LAUNCH: Qpain®

16/10/2023|All articles, Product launches|

Qpain® is a new topical anti-inflammatory cutaneous solution, containing diclofenac sodium 1.5% w/w, indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee. – Qpain® contains DMSO which enhances the absorption of diclofenac from the skin and reaches the focus of pain and inflammation directly. Ideal for those who cannot [...]

Read More

NEW PRODUCT LAUNCHING: Nitrofurantoin/IASIS® oral susp. – 1st Choice, Prevention & Treatment of UTIs

29/06/2023|All articles, Press Room, Product launches|

IASIS PHARMA is pleased to announce the Nitrofurantoin/IASIS oral susp. launching in the oral suspension formulation. This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A. Each 5ml of oral suspension Nitrofurantoin/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature, [...]

Read More

NEW PRODUCT LAUNCH: ETROZAC®

20/09/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the release of its new product ETROZAC®. ETROZAC® active substance is etoricoxib which is a selective cox-2 inhibitor. ETROZAC® is indicated for the relief of the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis and the pain and symptoms of inflammation associated with Acute Gout. ETROZAC® is indicated for the [...]

Read More

NEW PRODUCT LAUNCH: Rami – Amlo plus®

17/09/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the release of the new product Rami – Amlo plus® Rami – Amlo plus® is an original (prototype) fixed dose combination of Ramipril – Amlodipine -Hydrochlorothiazide Rami – Amlo plus® is indicated for the treatment of hypertension. Available in packs of 30 capsules, in a wide dosage range: Rami [...]

Read More

COVED® NEW PRODUCT LAUNCH

23/04/2021|All articles, Product launches|

IASIS PHARMA has successfully launched COVED® to the Greek market. COVED® (Bisphosphonates, combinations) is a fixed dose combination of two active ingredients: Alendronic acid (as alendronate sodium trihydrate) (70mg) & Cholecalciferol (Vitamin D3) (5.600 I.U). COVED® 70 mg / 5,600 IU is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D [...]

Read More

GLUCOPLUS®1.000mg NEW 60 F.C. TABS PACKAGE

05/04/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the launch of the new 60 f.c. tabs packaging for GLUCOPLUS® 1.000mg (Metformin hydrochloride). Both GLUCOFREE® & GLUCOPLUS® (active ingredient: metformin hydrochloride) belong to the broader category of Oral Hypoglycemic Agents (OHAs) for the treatment of Type 2 Diabetes Mellitus (T2D) as first-line therapy. GLUCOFREE® is available in 850mg metformin hydrochloride, [...]

Read More
Load More Posts

IASIS PHARMACEUTICALS HELLAS S.A.
PHARMACEUTICAL & COSMETICS INDUSTRY

All rights reserved - Copyright 2016 Iasis Pharma. Designed & Developed by JUST